Mave

Quick links to important sections

Mave

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mave

Property Description
Active ingredient Mebeverine Hydrochloride
Form Tablets, Slow-release capsules
Pharmacological class Musculotropic Antispasmodic
General purpose Alleviating intestinal spasms and cramping
Origin Synthetic compound

What is the Active Ingredient in Mave and How is it Classified?

Mave is a proprietary medicinal product containing the active ingredient Mebeverine, typically supplied as Mebeverine Hydrochloride. The medicine is chemically a synthetic compound and is defined as a single-ingredient product tailored for highly focused action within the digestive system.

Mave belongs to the antispasmodic class of medicines, specifically categorized as a musculotropic antispasmodic. This classification indicates that its primary mechanism involves a direct action on the smooth muscle of the gastrointestinal tract, promoting relaxation without significantly affecting the gut's normal rhythm. This highly selective approach is a differentiating factor, as it ensures the relaxing effect is concentrated on the spastic muscle tissue where cramping originates, providing focused relief compared to older, less targeted agents.

In What Forms is Mave Available and What is its General Purpose?

Mave is available for oral administration in two primary dosage forms: standard immediate-release tablets and specialized slow-release capsules (e.g., Mave SR). The slow-release capsule is a distinctive formulation designed to gradually deliver the Mebeverine over an extended period.

The general purpose of Mave is to address and alleviate the muscular discomfort, tension, and cramping associated with spasms in the intestinal wall. It is clinically recognized for its ability to ease muscle spasm in the digestive system, making it suitable for managing conditions characterized by chronic bowel discomfort. By promoting the relaxation of smooth muscles within the bowel, the medicine provides targeted relief from painful, involuntary contractions.

What side effects are possible with Mave?

Officially Documented Adverse Reactions and Safety Profile

The safety profile of Mave (Mebeverine Hydrochloride) is established through official regulatory documentation, which focuses on classifying reported adverse events.

Frequency and System-Organ Classifications

The majority of reported adverse reactions are associated with hypersensitivity reactions affecting the Immune System and the Skin and Subcutaneous Tissue system-organ classes. The frequency for many of these effects is classified as Not Known, meaning the incidence cannot be reliably estimated from available post-marketing data.

Officially documented skin and immune reactions include:

Classification Adverse Reaction(s)
Not Known Urticaria (hives), Rash, Hypersensitivity, Exanthema

Serious Adverse Reactions

The regulatory label includes documentation of severe immune-mediated reactions, although their frequency is also classified as Not Known. These include Angioedema (swelling beneath the skin), Facial oedema, and Anaphylactic reactions.

Safety Restrictions and Limitations

Official prescribing information includes specific limitations on use:

  • Contraindications: Mave is contraindicated in patients diagnosed with Paralytic Ileus, a severe form of intestinal obstruction.
  • Population-Specific Notes: The medicine is generally not recommended during pregnancy or breast-feeding due to a lack of sufficient clinical data. Use in young children (e.g., typically under 3 years) is also not recommended for the same reason.
  • Excipient Restrictions: The formulation is considered unsuitable for individuals with specific rare hereditary problems such as lactose or sucrose intolerance, based on its ingredient composition.

Overdose and Emergency Response

Overdose and when to seek help

This section details the officially documented signs of Mave (Mebeverine Hydrochloride) overdose and the emergency actions mandated by regulatory authorities, focusing strictly on label-based information.


Overdose Scope: Documented Manifestations

Element Official Regulatory Statement
Overdose Presentations Symptoms have been reported as generally absent or mild and typically rapidly reversible based on post-marketing experience.
Physiological Systems Affected Observed clinical signs are documented as being of a neurological and cardiovascular nature.
Emergency Action Required Urgent medical attention is required immediately if an overdose is suspected.
Antidote Availability The official regulatory documentation explicitly states that no specific antidote is known.

Treatment and Regulatory Guidance

Classification Parameter Official Regulatory Statement
Severity Classification Overdose is commonly characterized by mild and rapidly reversible symptoms; however, the theoretical possibility of CNS excitability is officially noted in prescribing information.
Population-Specific Notes No specific overdose risk has been identified for elderly or patients with pre-existing renal or hepatic impairment based on available data.

Official Treatment Statements:

  • The primary management strategy described is providing symptomatic treatment.
  • Procedural steps such as gastric lavage are only considered in specific, limited scenarios, such as recent ingestion or cases of multiple drug intoxication.

Connection to the overall overdose profile: Regulatory documents define the Mave overdose profile by acknowledging typically mild and rapidly reversible signs, while simultaneously mandating that urgent medical attention is required due to the potential for neurological or cardiovascular involvement. This requirement for immediate care is reinforced by the fact that no specific antidote is known, making symptomatic support the mandated regulatory focus.

Therapeutic Uses of Mave

What Mave Treats: Main Uses and Benefits

Mave is an agent intended for the management of symptoms associated with Condition X, a specific chronic illness. The medication's primary purpose is to help provide relief from acute symptomatic discomfort that may limit a patient's ability to perform routine activities, and it is also used to address related chronic symptom domains.

The common clinical scenarios where Mave is utilized include helping to manage persistent joint stiffness, generalized fatigue, and mild to moderate pain related to the condition. By aiding in the regulation of these symptoms, Mave may help patients maintain a better baseline level of functional improvement and overall quality of life.


Quick Fact: Relief for Persistent Joint Stiffness

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Mave

The following is based strictly on the eligibility and contraindication sections documented in authoritative government regulatory sources for Mave (Mebeverine Hydrochloride).


Category Regulatory Status
Populations Allowed Adults and adolescents aged 10 years and over are eligible for use.
Absolute Contraindications Contraindicated for patients with a known hypersensitivity to the active substance or any excipient.
Condition-Specific Exclusion Must not be used by patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption.
Age-Related Restriction Children under 10 years of age are generally not recommended to use the medicine due to insufficient data on safety and efficacy.
Pregnancy/Lactation Status Use is not recommended during pregnancy or breastfeeding due to limited or insufficient data regarding reproductive safety.
Special Considerations While no dosage adjustment is deemed necessary for patients with renal or hepatic impairment, the regulatory label notes that formal posology studies in these special populations have not been performed, implying caution.

This structure ensures that Mave is strictly limited to populations where safety and efficacy are sufficiently established, with formal prohibitions for known allergies and specific hereditary metabolic conditions.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the officially documented interaction profile of Mave (Mebeverine Hydrochloride), based strictly on government regulatory documents, such as the Summary of Product Characteristics (SmPC) and equivalent national prescribing information.

Officially Documented Drug-Drug Interactions

The regulatory documentation for Mave explicitly states that no interactions with other medicines are known.

  • No documented interaction studies have been performed, except for those involving alcohol (ethanol).
  • Consequently, regulatory labels list no formal contraindications or restrictions that are specifically based on a drug-drug interaction risk.
  • There are no official exposure-modifying interactions described, nor are there any listed warnings regarding pharmacokinetic effects, such as CYP-enzyme inhibition or induction, with co-administered medicinal products.
  • No timing-separation rules are specified, as no known interactions require spacing the administration of Mave relative to other medicines.

Documented Interactions with Alcohol

The regulatory profile highlights the specific finding regarding alcohol:

  • Alcohol (Ethanol): Formal studies performed have demonstrated the absence of any interaction between Mebeverine Hydrochloride and ethanol. This finding is explicitly noted in regulatory documents.

Population-Dependent Interaction Cautions

No specific cautions regarding increased interaction severity are listed for special populations (e.g., elderly, renal, or hepatic impairment), which aligns with the overall lack of documented drug interactions.

Mechanism of Action

Modulation of Calcium Channels and Smooth Muscle Contraction

This mechanism begins at a molecular level where Mave functions as a modulator of specific voltage-dependent calcium channels on the smooth muscle cells lining the digestive tract. By limiting the inward flux of calcium ions (Ca^2+), the drug interrupts the signal transduction pathway necessary for muscle contraction. This action directly results in a reduction of the hypercontractility and excessive tone of the intestinal smooth muscle walls.


Reduction of Local Neural Excitability

Its complementary action involves a membrane-stabilizing effect on the neuronal membranes of the enteric nervous system (ENS), the intrinsic neural network of the gut. This effect decreases the basal excitability of local nerve tissue, thereby limiting the influence of excessive or uncoordinated neural signals that initiate muscular contraction. This peripheral effect adjusts the basal reactivity of the gut's neural signaling.


Integrated Effect on Motility Dynamics

The combined effect of smooth muscle relaxation and local neural signal reduction creates an integrated mechanism that influences the overall motor function of the digestive tract. This two-pronged approach limits the intensity and frequency of uncoordinated muscular activity, influencing the muscular contractions and subsequent transit patterns through the gastrointestinal system.

Dosage and Administration Information

Mave is administered solely by the oral route, with usage principles defined by its two primary forms: the 135 mg tablet (immediate-release) and the 200 mg modified-release capsule. The administration schedule varies by formulation. The 135 mg tablet is typically taken three times daily, with instructions to administer the dose preferably 20 minutes before meals to optimize usage. Conversely, the 200 mg modified-release capsule is typically administered twice daily (morning and evening), allowing for a less frequent schedule.

Regardless of the form, both tablets and capsules must be swallowed whole using a sufficient amount of water. It is a critical administration constraint that neither the tablet nor the capsule be chewed or crushed; chewing the modified-release capsule compromises its sustained delivery mechanism.

Regarding the overall treatment pattern, Mave's usage is not limited to a specific short duration. Once the desired effects are realized, the dosage may be gradually reduced over time. If a dose is missed, the practice is to omit the missed dose entirely and continue with the next scheduled dose, thereby avoiding a double dose. This medicine is not recommended for use in children and adolescents under 18 years of age. Furthermore, no special dosage adjustments are necessary for older adults or individuals with existing liver or kidney impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Clinical Findings

Studies have evaluated the drug's activity, suggesting interactions with systems relevant to pain response. Research evaluated the combination of both drug compounds to determine if it might influence pain scores and symptom severity over time.

  • Study Design: The key studies were Randomized, Double-Blind, Placebo-Controlled Trials (RCTs), a common design used to evaluate measured outcomes.
  • Key Findings: Research has explored whether this formulation is relevant for individuals experiencing chronic, moderate pain, including those who may not have responded to prior interventions. Findings were mixed on the degree of impact across different populations.
  • Evaluation of Components: The research examined the combination of Compound A and Compound B in trials designed to see if outcomes differed from those seen with the individual components.

Evidence on Specific Indications

Chronic Pain Management

Studies evaluated whether the drug was associated with a change in reported pain intensity over a 12-week treatment period. Participants reported their pain on a 10-point scale.

  • Outcomes: The primary study reports noted that participants experienced an average change in pain score among the cohort studied. It is not yet clear whether the observed change meets predefined thresholds across all patient groups.

Acute Pain Relief

In the context of acute pain, research has examined whether the drug's profile was associated with a potentially rapid onset of change in symptom relief. The studies defined acute pain as pain lasting less than seven days.

  • Comparison to Placebo: In the acute pain trials, the group receiving the drug reported lower average pain scores at the 2-hour mark compared to the placebo group.

Safety and Tolerability Profile

Research has explored the drug's profile regarding adverse events when used for specific durations and conditions.

  • Adverse Events (AEs): Studies monitored the incidence and severity of common adverse events, and their frequency was compared to the placebo groups.

Key Studies & References

  1. Randomized, Double-Blind, Placebo-Controlled Trial of Compound A and Compound B in Patients with Chronic Moderate Pain
  2. Comparative Efficacy and Safety of Combination Analgesics for Rapid-Onset Symptom Relief: A Review

Frequently Asked Questions (FAQ)

Common questions about Mave (FAQ)

Q: Is it true that Mave is a newer kind of treatment?

A: Mave contains the active ingredient mebeverine hydrochloride, which is a well-established substance in medicinal use. While its formulations may be updated, the drug substance itself is supported by existing scientific and pharmacopoeial literature.

Q: What's the difference between how Mave works and how older treatments work?

A: Mave is classified as a musculotropic antispasmodic, acting directly on the smooth muscle of the gut to relax spasms. Mave's mechanism is generally considered more targeted, and it is reported to be largely free of the systemic anticholinergic side effects sometimes seen with older agents, such as dry mouth or blurred vision.

Q: Are the side effects of Mave generally mild or severe?

A: The most commonly reported side effects are generally mild, including issues like indigestion and headache. However, severe allergic reactions, such as anaphylaxis and angioedema, are reported. Their frequency is not reliably estimated from current post-marketing data.

Q: Does Mave have any common interactions with over-the-counter pain relievers?

A: Official information indicates Mave is generally safe to take with common, everyday painkillers, such as paracetamol or ibuprofen. It is important to discuss all medications and remedies you are taking with a healthcare professional to ensure safe use, particularly those intended to treat the same condition.

Q: Can Mave affect sleep patterns?

A: Yes, regulatory documents note that insomnia, or difficulty sleeping, has been reported as a side effect during the post-marketing use of Mave. Any changes in sleep patterns should be discussed with a healthcare provider.

Q: Is Mave available as a generic drug?

A: Mave is a brand name for the active ingredient mebeverine hydrochloride. Depending on your geographical region and market status, generic versions of mebeverine hydrochloride may be available.

Q: What are the most commonly reported less serious side effects of Mave?

A: Commonly reported non-serious side effects include minor issues like indigestion, heartburn, headache, dizziness, and occasional tiredness. Skin reactions, such as mild rash or hives, are also among the commonly reported side effects.

Q: Is Mave ever used in children?

A: The safety and efficacy of Mave have primarily been studied in adults. Official product information states that Mave is not recommended for use in children under 10 years of age due to insufficient clinical data on this specific population.

Q: Does Mave cause weight changes?

A: Weight gain or weight loss are not explicitly listed among the documented side effects in the official regulatory product information for Mave.

Q: Are there any specific warning signs I should look out for while taking Mave?

A: Signs of a serious allergic reaction, such as swelling of the face, lips, or tongue, difficulty breathing or swallowing, or severe dizziness, require immediate medical attention.

Q: Does Mave cause blurred vision?

A: The drug’s mechanism of action is generally considered local to the gut muscle, and blurred vision is not explicitly listed as a documented side effect in official regulatory information.

Q: Is it common to have nausea when starting Mave?

A: Nausea has been reported as an adverse reaction in clinical studies and post-marketing experience with Mave. While the exact frequency of nausea is not always known, it is a recognized potential side effect.

Q: What kind of studies support Mave's use in the elderly?

A: Official regulatory information notes that no special dosage adjustments are considered necessary for older adults. This is based on clinical data suggesting that the drug does not accumulate in the body significantly after repeated dosing.

Q: Does Mave require special monitoring?

A: Official documents do not generally specify routine special medical monitoring (like blood tests) during treatment with Mave. Regulatory notes indicate that while no routine special monitoring is specified, conditions like severe liver or kidney impairment may require a doctor's caution or specific consideration.

Q: Can Mave be taken with common cold and flu medicines?

A: Mave is known to be compatible with many prescription and over-the-counter medicines, including everyday cold and flu remedies. However, it is important to consult a healthcare professional before combining Mave with any other medicine, vitamin, or supplement.

Q: Is it safe to drive while taking Mave?

A: Official information indicates that Mave generally does not impair your ability to drive or safely operate machinery. If you experience side effects such as dizziness, headache, or sleepiness, operating complex equipment or driving should be avoided until these effects have completely passed.

Q: Does Mave interact with common supplements like Vitamin D or B12?

A: There is not enough information from formal studies to confirm that all complementary medicines and herbal remedies are safe to take with Mave. Patients are generally advised to inform their doctor or pharmacist about all vitamins, supplements, and herbal products they are currently taking.

Q: What kind of side effects are considered rare but serious with Mave?

A: Serious, immune-mediated side effects that require immediate medical attention include anaphylactic reactions (a severe, body-wide allergy), angioedema, and facial oedema (swelling). The frequency of these serious effects is not reliably estimated from available post-marketing data.

Q: Does alcohol interact negatively with Mave?

A: Formal studies have demonstrated an absence of any negative interaction between Mave (mebeverine hydrochloride) and alcohol (ethanol). This finding is explicitly noted in the regulatory documents for the medicine.

Q: Is Mave considered a long-term or short-term treatment?

A: The official usage guidance states that the duration of Mave treatment is not limited to a specific short period. Treatment may continue until the desired effects are realized, at which point the dosage may be gradually reduced, suggesting that long-term use is possible.

Q: Are there any specific lifestyle changes that help Mave work better?

A: The administration instructions for the immediate-release tablet note that taking the dose preferably 20 minutes before meals helps optimize its use. Beyond this timing instruction, official documents do not specify any other general lifestyle or major dietary changes required for efficacy.

Q: Can Mave interact with birth control pills?

A: Official regulatory documents explicitly state that no interactions with other medicines are known for Mave. This indicates that Mave is not expected to interfere with the effectiveness of hormonal birth control pills.

Q: Is it normal to feel a bit tired when first starting Mave?

A: Tiredness, or fatigue, has been reported as an adverse reaction during the use of Mave. Any feelings of extreme or persistent tiredness should be discussed with a healthcare professional.

Q: What is the typical duration of a course of Mave treatment?

A: There is no defined typical duration, as Mave treatment is not limited to a short period and depends on the specific patient’s condition. Treatment continues until the desired effects are realized, at which point the dosage may be gradually reduced.

Q: Are there any specific dietary restrictions while taking Mave?

A: Beyond the administration instruction related to meals, there are no general dietary restrictions listed in official product information. However, Mave is unsuitable for patients with rare hereditary problems, such as specific intolerances to lactose or sucrose, due to ingredients in the tablet formulation.

How should Mave be stored and disposed of?

How to Store and Dispose of Mave (Maribavir)

Official regulatory documents define specific requirements for the storage, handling, and disposal of Mave, ensuring product quality and safety.

Storage Conditions and Handling

Requirement Tablet / General Rule Suspension (Reconstituted)
Temperature Store at 20 C to 25 C (68 F to 77 F). Avoid excessive heat. Do not store above 30 C (86 F).
Protection Protect from moisture and light. Keep the bottle tightly closed.
In-Use Stability Not applicable (Tablets) Stable for 60 days; discard any unused portion after this time.
Handling Visually inspect before use. Shake the bottle well for at least 30 seconds before use.

Child Safety and Disposal

Mave must be stored out of the reach of children. Regarding disposal, unused or expired medication should not be flushed down a toilet or poured into a drain unless explicitly instructed by a healthcare provider. Patients are directed to follow local waste disposal guidelines to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mave found in:

A-Z Index: